Get the Stockscreener App
0.4438
4.27%
-0.0198
After Hours:
.46
0.0162
+3.65%
Harvard Bioscience Inc stock is traded at $0.4438, with a volume of 1.66M.
It is down -4.27% in the last 24 hours and down -4.97% over the past month.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
See More
Previous Close:
$0.4636
Open:
$0.47
24h Volume:
1.66M
Relative Volume:
0.15
Market Cap:
$26.29M
Revenue:
$106.79M
Net Income/Loss:
$-8.73M
P/E Ratio:
-2.219
EPS:
-0.2
Net Cash Flow:
$10.81M
1W Performance:
-13.61%
1M Performance:
-4.97%
6M Performance:
-78.97%
1Y Performance:
-84.43%
1-Day Range:
$0.4207
$0.4849
1-Week Range:
$0.4207
$0.5509
52-Week Range:
$0.2813
$3.60
Harvard Bioscience Inc Stock (HBIO) Company Profile
Name
Harvard Bioscience Inc
Sector
Industry
Phone
(508) 893-8999
Address
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
0.4438 | 26.29M | 106.79M | -8.73M | 10.81M | -0.20 |
|
ISRG
Intuitive Surgical Inc
|
543.41 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
172.25 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
88.28 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
258.00 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
218.80 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-10-23 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-09-20 | Initiated | Northland Capital | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-08-19 | Downgrade | Janney | Buy → Neutral |
| Jan-24-18 | Reiterated | Janney | Buy |
| Jan-23-18 | Reiterated | The Benchmark Company | Buy |
| Nov-17-16 | Initiated | Singular Research | Buy |
| Jul-28-15 | Initiated | The Benchmark Company | Buy |
View All
Harvard Bioscience Inc Stock (HBIO) Latest News
Financial Fitness Check: Examining Harvard Bioscience Inc (HBIO)’s Key Ratios - DWinneX
Major Improvements In Harvard Bioscience Inc (HBIO) Stock Need To Be Considered - Stocksregister
Harvard Bioscience appoints new board member as director steps down - Worcester Business Journal
What Did We Find About Insider Trading At Harvard Bioscience Inc (NASDAQ: HBIO)? - Stocksregister
Harvard Bioscience appoints new board member By Investing.com - Investing.com India
Harvard Bioscience Approves Incentive Plan Amendment - TipRanks
Harvard Bioscience appoints new board member - Investing.com
Harvard Bioscience Appoints John Duke to Board of Directors | HB - GuruFocus
Harvard Bioscience Appoints John Duke to Board of Directors - The Manila Times
Harvard Bioscience Strengthens Board with Ex-Corning Life Sciences Leader John Duke, Names New Lead Director - Stock Titan
Little Excitement Around Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Revenues As Shares Take 26% Pounding - simplywall.st
Harvard Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Harvard Bioscience price target lowered to $3 from $4.50 at Benchmark - Yahoo Finance
Harvard Bioscience outlines Q2 revenue target of $18M–$20M amid product launches and cost actions - MSN
Harvard Bioscience (HBIO): Analyst Lowers Price Target, Maintains Rating | HBIO Stock News - GuruFocus
Harvard Bioscience (HBIO) Target Price Reduced Amid Market Challenges | HBIO Stock News - GuruFocus
Harvard Bioscience (HBIO) Target Price Reduced Amid Market Chall - GuruFocus
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2025 Earnings Call Transcript - Insider Monkey
Harvard Bioscience Inc (HBIO) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Innovations - GuruFocus
Earnings call transcript: Harvard Bioscience Q1 2025 revenue beats forecast By Investing.com - Investing.com South Africa
Harvard Bioscience Announces First Quarter 2025 Financial Results - GlobeNewswire
Harvard Bioscience: Q1 Earnings Snapshot - MySA
Harvard Bioscience (HBIO) Reports Q1 2025 Highlights Amid Financ - GuruFocus
Harvard Bioscience Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Harvard Bioscience, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Harvard Bioscience earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
HBIO Reports Decline in Q1 Revenue Amid Market Challenges | HBIO Stock News - GuruFocus
Harvard Bioscience earnings matched, revenue topped estimates - Investing.com
Harvard Bioscience Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Harvard Bioscience, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:HBIO) - Seeking Alpha
Harvard Bioscience Q1 2025 slides: Revenue decline and goodwill impairment weigh on results - Investing.com Canada
Earnings call transcript: Harvard Bioscience Q1 2025 revenue beats forecast - Investing.com
Harvard Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Harvard Bioscience Inc Reports Q1 2025 Revenue of $21.8M, Exceed - GuruFocus
Harvard Bioscience Inc Reports Q1 2025 Revenue of $21.8M, Exceeding Estimates; Faces Net Loss Due to Goodwill Impairment - GuruFocus
Harvard Bioscience Q1 Net Income USD -50.34 Million - marketscreener.com
Harvard Bioscience Announces First Quarter 2025 Financial Results | HBIO Stock News - GuruFocus
Harvard Bioscience : Q1 2025 Harvard Bioscience, Inc. Earnings Conference Call - marketscreener.com
Harvard Bioscience Inc (HBIO) Q1 2025 Earnings Report Preview: W - GuruFocus
Harvard Bioscience Inc Stock (HBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):